FBLGFibroBiologics Inc
$0.7731
$0.0079
(1.01%)
Closed $0.7731
$0.0154
(1.99%)
After Hours
Reported EarningsOct 31
Mkt Cap$4.75M
Vol112,710.00
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors PR Newswire HOUSTON, July 9, 2026 Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trivedi Institute...
PR Newswire
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial PR Newswire HOUSTON, July 7, 2026 Company...
PR Newswire
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference PR Newswire HOUSTON, June 30, 2026 HOUSTON, June 30, 2026 /PRNewswire...
PR Newswire
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire HOUSTON, June 29, 2026 $3.0 million upfront with up to...
PR Newswire
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire HOUSTON, June 26, 2026 $3.0 million upfront with up to approximately $6.0 million...
PR Newswire
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers.read more...
Benzinga
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data...
Yahoo! Finance: News
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study
FibroBiologics releases CYWC628 batch for DFU trial, clears cGMP checks, prepares enrollment; interim data expected in Q3 2026.read more...
Benzinga
EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy
FibroBiologics completes first CYWC628 batch for diabetic foot ulcers trials, advances pipeline amid stock drop and recent reverse split.read more...
Benzinga
Hamid Khoja Acquires 30,000 Shares of FibroBiologics (NASDAQ:FBLG) Stock
FibroBiologics Inc. (NASDAQ:FBLG - Get Free Report) insider Hamid Khoja bought 30,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was acquired at...
MarketBeat
<
1
2
...
>
Latest FBLG News
ViewFibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
PR Newswire
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
PR Newswire
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
PR Newswire
Advertisement|Remove ads.